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Abstract
Background: Protein Kinase D1 is downregulated in its expression in invasive ductal carcinoma of the breast and in invasive
breast cancer cells, but its functions in normal breast epithelial cells is largely unknown. The epithelial phenotype is
maintained by cell-cell junctions formed by E-cadherin. In cancer cells loss of E-cadherin expression contributes to an
invasive phenotype. This can be mediated by SNAI1, a transcriptional repressor for E-cadherin that contributes to epithelial-
to-mesenchymal transition (EMT).
Methodology/Principal Findings: Here we show that PKD1 in normal murine mammary gland (NMuMG) epithelial cells is
constitutively-active in its basal state and prevents a transition to a mesenchymal phenotype. Investigation of the involved
mechanism suggested that PKD1 regulates the expression of E-cadherin at the promoter level through direct
phosphorylation of the transcriptional repressor SNAI1. PKD1-mediated phosphorylation of SNAI1 occurs in the nucleus
and generates a nuclear, inactive DNA/SNAI1 complex that shows decreased interaction with its co-repressor Ajuba. Analysis
of human tissue samples with a newly-generated phosphospecific antibody for PKD1-phosphorylated SNAI1 showed that
regulation of SNAI1 through PKD1 occurs in vivo in normal breast ductal tissue and is decreased or lost in invasive ductal
carcinoma.
Conclusions/Significance: Our data describe a mechanism of how PKD1 maintains the breast epithelial phenotype.
Moreover, they suggest, that the analysis of breast tissue for PKD-mediated phosphorylation of SNAI1 using our novel
phosphoS11-SNAI1-specific antibody may allow predicting the invasive potential of breast cancer cells.
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Introduction
E-cadherin mediated cell-to-cell contacts are important to the
structural integrity of epithelial cell layers. During tumorigenesis
epithelial tumor cells lose E-cadherin expression concomitantly
with acquisition of mesenchymal characteristics. This process has
been termed epithelial-mesenchymal transition or EMT [1]. Cells
undergoing EMT acquire a fibroblast-like shape and show
increased motility and invasiveness due to activation of a
mesenchymal gene expression program [2]. EMT-associated
cellular changes are loss of adherens junctions and epithelial cell
polarity, cell scattering due to loss of cytokeratin expression,
increased expression of N-cadherin and avb6 integrin, and
increased secretion of fibronectin and matrix metalloproteinases
[3,4].
In many types of cancers and tumor cell lines, transcriptional
repression by SNAI1 family members has emerged as a key
mechanism for the dynamic modulation of E-cadherin expression
and the induction of EMT [1,5,6,7]. Other SNAI1 target genes
encoding proteins maintaining the polarized epithelial structure
include cytokeratins 17/18 [8], collagen 2a1 [9], Mucin1 (MUC1),
ZEB1 [8] and SNAI1 itself [10]. Several studies have correlated
SNAI1 expression with tumor growth and invasion [11], lymph
node metastasis [12,13], effusion [14,15], distant metastasis
[16,17,18], chemoresistance [19] and the recurrence of tumors
[20].
The SNAI1 family of transcriptional repressors consists of three
members SNAI1 (Snail1, Snail), SNAI2 (Slug, Snail2) and SNAI3
(Smuc, Snail3). They all share a common structural organization
consisting of a highly conserved C-terminal region, which harbors
four zinc fingers functioning as sequence specific DNA-binding
domains for E2-box type DNA sequences C/A (CAGGTG) [1,4].
Dependent on the target gene, repressor capacity requires SNAI1
interaction with the co-repressors Ajuba, PRMT5 and SIN3a, or
histone deacetylases 1 and 2 (HDAC) [21,22,23]. Some of these
interactions (i.e. binding to Ajuba) are dependent on the SNAG-
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transcriptional level, but also at the protein level. For example, the
kinase GSK3b phosphorylates SNAI1 at several serine residues in
its NES (nuclear export sequence) and its destruction box leading
to SNAI1 nuclear export, ubiquitination and degradation
[7,18,25,26]. However, in many cells GSK3b is negatively-
regulated by Akt and thus it is unclear of how SNAI1 is kept in
check. Recently, an additional regulation of SNAI1 through
phosphorylation at serine 11 was suggested [27,28,29]. Phosphor-
ylation of SNAI1 at this site can mediate its nuclear export via
binding to 14-3-3s [27].
Protein Kinase D (PKD) is a serine/threonine kinase that
belongs to the family of calcium/calmodulin-dependent kinases
(CaM-Ks) [30,31]. PKD is a sensor for oxidative stress [32,33], but
is also activated by growth factors and subunits of trimeric G-
proteins [34] and small RhoGTPases such as RhoA [35,36]. In
invasive ductal carcinoma of the breast PKD1 is downregulated in
its expression [37]. Moreover, in breast, prostate and gastric
cancer cell lines PKD1 expression and activity reversely correlate
with the migratory potential and invasiveness [37,38,39]. Several
PKD1 targets can contribute to its negative-regulatory function on
cell motility. These include the phosphatase slingshot [40,41], the
Par-1 polarity kinase [42], b-catenin and E-cadherin [38,43].
It is not known if PKD has a role in maintaining the epithelial
phenotype of normal cells. Here we show that inactivation of
PKD1 in normal mammary gland epithelial cells induces EMT
leading to a mesenchymal phenotype. We show that PKD1
maintains E-cadherin levels in epithelial cells by regulating SNAI1
through direct phosphorylation. This leads to a loss of SNAI1
transcriptional repressor activity, although phosphorylated SNAI1
stays bound to its target sequence at the E-cadherin promoter.
Moreover, such phosphorylation-mediated regulation of SNAI1
seems to occur in vivo in normal breast ductal tissue and is
decreased or lost in invasive ductal carcinoma, indicating that the
previously reported loss of PKD1 expression in invasive breast
cancer may directly transfer to E-cadherin inhibition through
SNAI1.
Results
PKD1 conserves the epithelial phenotype in normal
epithelial mammary gland cells
In breast cancer cells PKD1 is a negative-regulator of cell
migration and invasion [41]. Consequently, PKD1 is downregu-
lated in its expression in human invasive ductal carcinoma of the
breast [37]. Here we investigated if PKD1 can preserve an
epithelial phenotype by blocking epithelial to mesenchymal
transition of normal breast cells, an initial step that leads to
increased cell motility. To test this we used normal murine
mammary gland epithelial cells (NMuMG), which in response to
TGFb1 undergo a full EMT, in accordance with morphological
changes to a mesenchymal phenotype including upregulation of
N-cadherin and downregulation of E-cadherin and cytokeratin
expression at the molecular level (Fig. 1A). Under normal growth
conditions, NMuMG cells show high levels of endogenous, basally-
active PKD1 as measured with a phospho-specific antibody
(pS738/742-PKD) directed against the phosphorylated PKD
activation loop. Treatment with TGFb1 decreased PKD activity
to approximately 20% of its basal activity, suggesting that PKD1
inhibition is one mechanism of how TGFb1 induces EMT
(Fig. 1B). By comparing this basal activity to PKD1 activity in
cells either stimulated with the phorbol ester PMA (maximum
activation) or the PKD1 activators bradykinin and EGF, we found
that under normal growth conditions in NMuMG cells approx-
imately one third of the PKD1 pool is in its active form (Fig. 1C).
Moreover, expression of a constitutively-active PKD1 allele
(PKD1.CA, PKD1.S738E.S742E mutant) increased basal E-
cadherin levels. It also decreased TGFb1-mediated EMT as
measured by decreased expression of N-cadherin, and maintained
basal E-cadherin levels (Fig. 1D). When expressing a kinase-dead
variant of PKD1 (PKD1.KD, PKD1.K612W mutant) we further
found that the inhibition of PKD1 in these cells alone is sufficient
to induce an EMT-like cellular phenotype (Fig. 1E). These data
indicate that PKD1 in normal murine mammary gland cells is
constitutively-active in its basal state and prevents EMT.
PKD1 regulates E-cadherin expression in epithelial cells
EMT is linked to the loss of expression of E-cadherin, which is a
marker for the normal epithelial phenotype. The expression of a
kinase-dead PKD1 allele in NMuMG cells correlated with
decreased E-cadherin expression (Fig. 2A, arrows). Moreover, in
other epithelial cell lines including MCF-7 and MDCK, E-
cadherin expression was increased when a constitutively-active
PKD1 was expressed and decreased when the kinase-inactive
PKD1 mutant was expressed (Fig. 2B and Fig. S1). Finally, the
use of an E-cadherin promoter gene reporter demonstrated that
PKD1 similarly affects E-cadherin at the gene expression level
(Fig. 2C).
Active PKD1 directly phosphorylates SNAI1
In order to determine if PKD1 maintains the epithelial
phenotype through direct phosphorylation of transcriptional
repressors of the E-Cadherin gene, we analyzed the sequences of
SNAI1, Slug/SNAI2, SNAI3 and Twist for the PKD phosphor-
ylation consensus motif LXRXXS (with X as any amino-acid and
S as the targeted serine residue) [44]. Ideal PKD phosphorylation
motifs were detected in SNAI1. Of these S11 and its surrounding
motif is 100% identical in human, mouse and rat SNAI1 (Fig. 3A).
In order to demonstrate direct phosphorylation by PKD1, we
performed in vitro kinase assays using bacterially-expressed,
purified wildtype GST-SNAI1 or GST-SNAI1.S11A fusion
proteins and baculovirally-expressed and purified PKD1. Using
a pMOTIF antibody that recognizes PKD substrates (previously
described in [45]), we found that S11 is the only phosphorylation
site for PKD1 in SNAI1 (Fig. 3B left side). We also generated a
phosphospecific antibody for S11-phosphorylated SNAI1 to
directly demonstrate phosphorylation by PKD1 (Fig. 3B, right
side). Moreover, PKD1-mediated phosphorylation of SNAI1 at
this residue could be demonstrated in cells with the pMOTIF
(Fig. 3C) and the pS11-SNAI1 antibody (Fig. 3D). To determine
the relative stoichiometry of SNAI1 phosphorylation by PKD1 we
performed an in vitro kinase assay in presence of [c-
32P]ATP.
PKD1 phosphorylated SNAI1 to <1.0860.05 mol phosphate/
mol SNAI1 protein.
We and others previously have shown that PKD1-mediated
inhibition of cell motility is mediated through its activation by the
RhoGTPase RhoA [35,36]. Expression of active RhoA increased
SNAI1 phosphorylation at S11 and this was blocked with both,
kinase-dead PKD1 (Fig. 3E, Figure S2) as well as when PKD1/2
was knocked-down (Fig. 3F, Figure S2). Moreover, in NMuMG
cells treated with TGFb1 nuclear PKD1 was inactive (as measured
by phosphorylation of its activation loop serines) and this
correlated with decreased phosphorylation of SNAI1 at S11
(Fig. 3G). Moreover, treatment of NMuMG cells with the PKD
inhibitor CID755673 decreased basal SNAI1 phosphorylation at
S11 (Fig. 3H), further supporting the principal conclusion that
active PKD1 may prevent EMT in these cells via phosphorylation
of SNAI1.
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PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e30459Figure 1. PKD1 conserves the epithelial phenotype in normal mammary gland cells. A: NMuMG cells were either left untreated or were
treated with TGFb1 (10 ng/ml) for 48 hours. Cell morphology was photographed (bar is 200 mm) and cells were harvested and analyzed for
expression of epithelial (E-cadherin, cytokeratin) and mesenchymal (N-cadherin) markers by Western blotting with anti-N-cadherin, anti-E-cadherin, or
anti-cytokeratin antibodies. Staining for actin (anti-actin) served as a loading control. B: NMuMG cells were treated with TGFb1 (10 ng/ml) for
24 hours. Endogenous PKD1 was immunoprecipitated (anti-PKD1) and analyzed for phosphorylation at its activation loop that correlates with its
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and does not alter its localization
Immunofluorescence staining of NMuMG cells with a PKD1-
specific antibody and DAPI showed that a subcellular pool of
endogenous PKD1 is localized in the nucleus (Fig. 4A). Moreover,
staining with our anti-pS11 antibody and DAPI showed basal
phosphorylation of nuclear SNAI1, most likely due to the basal
activity of nuclear PKD1 in these cells (Fig. 4B). To confirm
specificity, the pS11-SNAI1 antibody was incubated for one hour
with a 100-fold molar excess of the pS11-peptide used as antigen
prior to use in immunofluorescence. Moreover, immunoblotting of
nuclear preparations of control cells and cells with ectopic
expression of active PKD1 or RhoA indicated that PKD1 indeed
induces phosphorylation of SNAI1 at S11 in the nucleus (Fig. 4C).
The phosphorylation of SNAI1 by PKD1 did not induce its
translocation to the cytosol. This is supported by a mutational
analysis, where both, a SNAI1 mutant deficient in the PKD 1
phosphorylation site (SNAI1.S11A), or a SNAI1 mutant with
phospho-mimicking mutations for this site (SNAI1.S11E), did not
exit the nucleus (Fig. 4D and Fig. S3). Additionally, the
expression of a constitutively-active PKD1 mutant (GFP-
PKD1.CA) did not alter the localization of wildtype and S11A-
mutated SNAI1 (Fig. 4E). Taken together, this indicates that the
phosphorylation of SNAI1 at this residue occurs in the nucleus and
has no impact on its cellular localization.
SNAI1 binds to the E-cadherin promoter in presence of
active PKD1, but is ineffective in inhibiting E-cadherin
expression
Chromatin immunoprecipitation (ChIP) assays showed that in
presence of active PKD1 SNAI1 was still bound to the E-Cadherin
promoter, suggesting that its phosphorylation by PKD1 does not
impact its ability to bind to its target promoter (Fig. 5A). This is
further supported by the binding of a SNAI1 mutant that mimics
phosphorylation (SNAI1.S11E) to the E-cadherin promoter
(Fig. 5B). Moreover, using the anti-pS11-SNAI1 antibody, S11-
phosphorylated SNAI1 was immunoprecipitated with the E-
cadherin promoter in NMuMG cells, in which PKD1 is basally
active, and inhibition of PKD with CID755673 blocked this
interaction (Fig. 5C and Figure S4). However, the presence of
active PKD1 blocked SNAI1-mediated transcriptional repression
of E-cadherin expression as measured with E-cadherin gene
promoter luciferase assays (Fig. 5D, left side). Moreover, a
SNAI1.S11A mutant that lacks the phosphorylation site for PKD1
decreased E-cadherin expression (Fig. 5D, right side). These data
suggest that SNAI1, after its phosphorylation by PKD1, is neither
exported from the nucleus, nor does it lose its contact with the E-
cadherin promoter, but rather is impacted in its function as a
repressor of the E-cadherin gene.
Phosphorylation of SNAI1 decreases its binding to Ajuba
Since amino-acid S11 is next to the SNAG domain of SNAI1,
which is required for binding to the co-repressor Ajuba, we next
analyzed if phosphorylation of this residue impacts the interaction
of both proteins. Therefore we determined the interaction of
SNAI1 or the S11A or S11E SNAI1 mutants with Ajuba. We
found that SNAI1 co-immunoprecipitates with Ajuba and that this
interaction is increased when S11 is mutated to alanine, but
decreased when mutated to a glutamate mimicking its phosphor-
ylation (Fig. 6A). This suggests that PKD1-mediated phosphor-
ylation of SNAI1 at S11 may prevent SNAI1 from binding to
Ajuba and from exerting its repressor functions. This mechanism
may allow to transiently turn-off SNAI1 functions while it is bound
to its target promoter (Fig. 6B).
Loss of nuclear PKD activity and SNAI1 phosphorylation
at S11 are markers for invasive breast cancer
To determine in vivo relevance of our data obtained with cell
culture, we utilized our phosphospecific antibody directed against
PKD-phosphorylated SNAI1 in tissue microarrays of human
normal breast tissue and invasive ductal carcinoma (IDC). 40
tumor samples as well as 10 normal samples were analyzed. A
representative selection of samples is presented in Fig. 7. We found
that nuclear localization of active PKD1 in normal ductal epithelia
of the breast correlates with SNAI1 phosphorylation at S11 in the
nuclei of these cells (Figs. 7B and 7C). Moreover, in all samples of
IDC with decreased PKD activity a correlating decrease in SNAI1
phosphorylation at S11 in the nucleus of tumor cells was detected
(Fig. 7E–P), whereas total SNAI1 levels were comparable in all
samples including normal ductal epithelium. To confirm specificity,
the pS11-SNAI1 antibody was incubated for one hour with a 100-
fold molar excess of the pS11-peptide used as antigen prior to use in
immunohistochemistry (Fig. S5).
Discussion
Epithelial-mesenchymal transition (EMT), a program that is
activated in development, but also in adult tissue under
pathological conditions including fibrosis and epithelial neoplasia,
allows epithelial cells to acquire the phenotypical characteristics
and behavior of mesenchymal cells [46,47]. Normal mammary
gland epithelial cells NMuMG are a bona fide system for TGFb1-
induced EMT [48]. Here we show that TGFb1-induced
downregulation of PKD1 activity is a significant factor contrib-
uting to EMT in these cells (Fig. 1). This is underlined by
constitutive expression of a kinase-dead allele of PKD1, which
leads to a similar mesenchymal phenotype as observed after long-
term treatment with TGFb1( Fig. 1).
In prostate epithelia cells, PKD1 has been shown to stabilize cell
adhesions through interaction with E-cadherin and phosphoryla-
tion of b-catenin [43], but also by regulation of E-cadherin
expression [27]. Our data suggests that presence of active PKD1
maintains the epithelial phenotype of normal breast epithelial cells.
One of the mechanisms of how PKD1 may achieve this is by
maintaining high E-cadherin expression levels. Indeed a kinase-
dead PKD1 decreased E-cadherin expression levels (Fig. 2).
Decreased expression of E-cadherin is a pivotal event in EMT,
activity (anti-pS738/742-PKD), or samples were control stained for total PKD1 (anti-PKD1). C: Cells were stimulated with PMA (100 nM, 10 min), EGF
(50 ng/ml, 10 min), Bradykinin (0.5 mg/ml, 10 min) or left untreated. Endogenous PKD1 was immunoprecipitated and subjected to an in vitro kinase
assay using PKD substrate peptide. PKD1 activity is depicted relative to PMA-activated PKD1 (maximum activation). Equal immunoprecipitation was
controlled by SDS-PAGE and immunoblot (anti-PKD1). D: NMuMG cells were either transfected with control vector or with active PKD1 (PKD1.CA,
PKD1.S738E.S742E). 24 hours after transfection, cells were treated with TGFb1 (10 ng/ml) for 24 hours. Lysates were analyzed for expression of N-
cadherin, E-cadherin, expression of PKD1, or actin as a loading control. E: NMuMG cells were stably-transfected with vector control, wildtype PKD1 or
kinase-dead PKD1.K612W (PKD1.KD) Cell morphology was analyzed by brightfield microscopy (bar is 200 mm). Expression of endogenous and
overexpressed PKD1 was determined by Western blot analysis using an anti-PKD1 antibody. Immunoblotting for actin (anti-actin) served as loading
control.
doi:10.1371/journal.pone.0030459.g001
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through zinc finger transcriptional repressors such as SNAI1 [12].
Downregulation of E-cadherin was described for many epithelial
tumor types and is linked to poor prognosis and increased invasion
and metastasis [2]. Interestingly, induced expression of E-cadherin
can cause a reversion of the mesenchymal to an epithelial
phenotype (mesenchymal-epithelial transition) [11]. Based on our
results it will be interesting to test in future studies if a re-
expression of PKD1 in mesenchymal cell types can induce such a
transition to an epithelia phenotype.
In human samples of invasive ductal carcinoma (IDC), PKD1 is
downregulated in its expression [37] and activity (Fig. 7).
Additionally, PKD1 is downregulated in invasive breast cell lines
and a re-expression of active PKD1 completely blocks their
invasiveness in 2D and 3D cell culture [37]. Moreover, the
depletion of PKD1 from non-invasive MCF-7 using reverse
genetics induced invasiveness [37]. Similar functions for PKD1 on
tumor cell invasion were described for other cancers including
prostate and gastric cancer [38,39]. This suggests that in breast
cancer PKD1 is a molecular switch that regulates motility and its
effects on E-cadherin expression and EMT may be one of the
mechanisms it uses.
Our data suggest that PKD1 regulates E-cadherin expression
through phosphorylation of SNAI1. Phosphorylation of SNAI1 at
S11 was described by several laboratories [27,28] and initially
PKA was identified as the kinase mediating this phosphorylation in
vitro [28]. Recently, it was shown that PKD1 also can contribute to
SNAI1 phosphorylation at S11 [27]. Utilizing purified PKD1 and
Figure 2. PKD regulates E-cadherin expression in epithelial cells. A: NMuMG cells were transfected with GFP-tagged, kinase-dead PKD1
(PKD1.KD) and endogenous expression of E-cadherin was determined with immunofluorescence staining (anti-E-cadherin). DAPI staining served as a
nuclear marker (bar is 50 mm). B: MCF-7 cells were transfected with vector control, HA-tagged PKD1 or kinase-dead PKD1 (PKD1.KD). After 48 hours,
samples were analyzed by Western blot for E-cadherin expression (anti-E-cadherin) as well as expression of PKD1 (anti-PKD1). Staining for actin (anti-
actin) served as loading control. C: MCF-7 cells were transfected with vector control, HA-tagged constitutively-active PKD1 (PKD1.CA) or kinase-dead
PKD1 (PKD1.KD) as well as E-cadherin promoter luciferase gene reporter and renilla luciferase reporter. Induced luciferase activity was measured. Error
bars shown represent standard deviations. The asterisks indicate statistical significance (p,0.05) as compared to vector control.
doi:10.1371/journal.pone.0030459.g002
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PLoS ONE | www.plosone.org 5 January 2012 | Volume 7 | Issue 1 | e30459Figure 3. Active PKD1 directly phosphorylates SNAI1 at S11. A: The amino-acids surrounding serine 11 in SNAI1 form a PKD consensus motif
as it was described for S82 of Hsp27 and S978 of SSH1L. B: PKD phosphorylates SNAI1 at S11 in an in vitro assay. Bacterially-expressed and purified
GST (negative control), GST-SNAI1 or GST-SNAI1.S11A were incubated in a kinase reaction with purified active PKD1. Substrate phosphorylation was
detected using the pMOTIF antibody, which recognizes the phosphorylated PKD motif in PKD substrates [45] or with the novel pS11-SNAI1 antibody
specifically generated for this site. Control blots were performed for protein input (anti-PKD1, anti-GST). C, D: HeLa cells were transfected with
combinations of vector control, active PKD1 (PKD1.CA) and SNAI1 or SNAI1.S11A mutant as indicated. PKD-mediated phosphorylation of SNAI1 was
detected using the pMOTIF (C) or the pS11-SNAI1 (D) antibodies. E, F: HeLa cells were transfected with combinations of vector control, active RhoA
(RhoA.CA) and PKD1 or PKD1.KD mutant (E) or control shRNA and shRNA specific for PKD1/2 (F) as indicated and FLAG-tagged SNAI1. PKD-mediated
phosphorylation of SNAI1 was detected using the pS11-SNAI1 antibody. Samples were also control-stained for SNAI1 and PKD1 expression using anti-
FLAG or anti-PKD1 antibodies, respectively. Anti-GST control staining for RhoA.CA and GST control are depicted in Figure S2. G: NMuMG cells were
treated with TGFb1 (10 ng/ml) for 48 hours. Total cell lysates were analyzed for phosphorylation of endogenous SNAI1 at S11 (anti-pS11-SNAI1) or
PKD1 activity (anti-pS738/742-PKD) or total PKD1 expression (anti-PKD1) as indicated. H: NMuMG cells were treated with CID755673 (25 mM, 4 hr) or
left untreated as indicated. Total cell lysates were analyzed for phosphorylation of endogenous SNAI1 at S11 (anti-pS11-SNAI1) or SNAI1 expression
(anti-SNAI1).
doi:10.1371/journal.pone.0030459.g003
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phosphospecific pS11-SNAI1 antibody, we now provide proof
that SNAI1 is a direct target for PKD1 (Fig. 3). We also show that
this phosphorylation occurs in cells in response to ectopic PKD1
expression and to PKD1 activation (Fig. 3).
Phosphorylation of SNAI1 mediates its binding to 14-3-3
proteins [27,29], however, the consequence of this interaction
can have different outcomes. It was suggested that the formation
of complexes with 14-3-3 stabilizes SNAI1 interaction with its
co-repressors [29]. Others have shown a 14-3-3s-mediated
nuclear export and inactivation of SNAI1 after its phosphory-
lation at S11 [27]. SNAI1 exclusion from the nucleus and
proteosomal degradation is mediated through its phosphoryla-
tion by GSK3b [18] and at this point it is unclear if a connection
between both phosphorylation pathways exists. In NMuMG cells
neither mimicking of the phosphorylation, nor phosphorylation
of SNAI1 at S11 by active PKD1 led to its nuclear exclusion
(Fig. 4). Instead, after phosphorylation at S11, we observed a
Figure 4. Phosphorylation of SNAI1 by PKD1 occurs in the nucleus and does not alter its localization. A: Immunofluorescence staining
of NMuMG cells for endogenous PKD1 (anti-PKD1). The bar represents 10 mm. B: Immunofluorescence staining of NMuMG cells for S11-
phosphorylated SNAI1 (anti-pS11-SNAI1) in absence or presence of competing phospho-S11-peptide and nuclei (DAPI). The bar represents 10 mm.
C: HeLa cells were transfected as indicated and nuclear extracts were prepared and analyzed by Western blot for SNAI1 (anti-FLAG), pS11-SNAI1 (anti-
pS11-SNAI1) and nucleolin (anti-nucleolin, loading control). D: NMuMG cells were transfected with GFP control, GFP-SNAI1, GFP-SNAI1.S11A or GFP-
SNAI1.S11E mutants. Localization of GFP or GFP-tagged proteins was determined using immunofluorescence analysis (bar is 10 mm). E: NMuMG cells
were transfected with FLAG-tagged wildtype SNAI1 or SNAI1.S11A mutant and GFP-tagged, active PKD1 (PKD1.CA) as indicated and localization of
SNAI1 was determined by indirect immunofluorescence staining (anti-FLAG as primary antibody). The bar represents 10 mm.
doi:10.1371/journal.pone.0030459.g004
Figure 5. PKD1-regulated SNAI1 binds to the E-cadherin promoter, but is ineffective in its function. A: Hek293T cells were transfected
with vector control, SNAI1 or active PKD1 (PKD1.CA) and SNAI1 as indicated. SNAI1/DNA complexes were immunoprecipitated (anti-FLAG) after
crosslinking and precipitates were analyzed by PCR for the SNAI1-bound E-cadherin promoter. B: NMuMG cells were transfected with vector control,
SNAI1, SNAI1.S11A or SNAI1.S11E mutants. SNAI1/DNA complexes were immunoprecipitated (anti-FLAG) after crosslinking and precipitates were
analyzed by PCR for the SNAI1-bound E-cadherin promoter. C: NMuMG cells were treated with CID755673 (25 mM, 1 hr) or left untreated. Phospho-
S11-SNAI1/DNA complexes were immunoprecipitated (anti-pS11-SNAI1) after crosslinking and precipitates were analyzed by PCR for the pS11-SNAI1-
bound E-cadherin promoter. In experiments depicted in A–C, a PCR for the E-cadherin promoter using the input DNA as well as a ChIP using IgG
instead of the anti-FLAG antibody served as controls. D: Hek293T cells were transfected with vector control, SNAI1 or SNAI1.S11A mutant, active
PKD1 (PKD1.CA) or both and E-cadherin promoter luciferase reporter and renilla reporter plasmids. Induced luciferase activity was measured. Error
bars shown represent standard deviations. P values were acquired with the t test, using GraphPad software. Asterisks indicate statistical significance.
doi:10.1371/journal.pone.0030459.g005
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(Fig. 6). Since S11 is located next to the SNAI1 SNAG domain,
which contributes to Ajuba-SNAI1 complex formation [22], we
propose that phosphorylation of this residue may hinder this
interaction. This would explain why PKD1 increases E-cadherin
promoter activity although SNAI1 is still promoter-bound
(Fig. 5). Such a mechanism is a novel concept for SNAI1
regulation. It would allow transient quick changes in gene
regulation of epithelial cells, without inducing SNAI1 degrada-
tion. It is possible that this mechanism is also utilized when
cancer cells switch to an invasive tumor type or when metastases
are established at distant sites.
In vivo studies support these results. PKD1 activity and SNAI1
phosphorylation at S11 occur in normal breast ductal epithelium
and are decreased in IDC. This data not only confirms data
obtained in cell culture, but also indicates that SNAI1 is expressed
in normal ductal cells of the breast, where it is silenced by
phosphorylation (Fig. 7). However, this correlation needs to be
addressed in more detail in future studies with increased numbers
of tumor and normal samples to obtain statistical power. At this
point it is unclear why normal breast cells (Fig. 4A) and normal
ductal tissue (Fig. 7A–D) express SNAI1, but keep it in an S11-
phosphorylated, inactive state. One explanation is that some
aspects of nuclear SNAI1 signaling may be needed for maintaining
normal tissue or cell functions. Another possibility is that cells
utilize this mechanism to facilitate a rapid switch of gene
expression. Such signaling may be important for breast develop-
ment and involution, or when tumor cells switch from a motile
state to a more epithelial phenotype.
Taken together, our data show that PKD1 maintains the
normal epithelial phenotype by preventing EMT. As one possible
mechanism, we identify the direct phosphorylation of SNAI1, an
event that occurs in the nucleus and transiently turns off SNAI1
inhibitory functions, while it stays bound to its target E-cadherin
promoter. Our results contribute to the understanding of the
complex molecular mechanisms which regulate the transition from
normal epithelial cells to invasive tumor cells and may lead to new
insights into how this process may be inhibited or reversed.
Materials and Methods
Cell Lines, Antibodies and Reagents
MCF-7, MDCK, Hek293T, and Panc1 cells were maintained in
DMEM with 10% FBS. All cell lines were obtained from American
Type Culture Collection ATCC (Manassas, VA). NMuMG cells
were cultivated in DMEM plus 10% FBS and 10 mg/ml insulin.
TGFb1 was from Peprotech (Rocky Hill, NJ). Anti-GST, anti-PKD1
and anti-14-3-3 antibodies were from Santa Cruz (Santa Cruz, CA),
anti-HA, anti-FLAG (M2), anti-actin, anti-nucleolin from Sigma-
Aldrich (St Louis, MO), anti-E-cadherin from BD Biosciences (San
Diego, CA), anti-N-cadherin from Epitomics (Burlingame, CA), anti-
Snail (ab85931), anti-cytokeratin, anti-MYC and anti-GFP from
Abcam (Cambridge, MA), anti-pMOTIF (PKD substrate antibody)
and anti-pS744/742-PKD antibody (recognizes S738/S742-phos-
phorylated PKD1) from Cell Signaling Technology (Danvers, MA).
A rabbit polyclonal antibody specific for human SNAI1 phosphor-
ylated at S11 (anti-pS11-SNAI1 antibody) was raised by 21 Century
Biochemicals (Marlboro, MA) using Ac-FLVRKP[pS]DPNRKPC-
Figure 6. Phosphorylation of SNAI1 decreases its binding to Ajuba. A: HeLa cells were co-transfected with MYC-tagged Ajuba and vector
control, and FLAG-tagged wildtype SNAI1, SNAI1.S11A or SNAI1.S11E mutants as indicated. Ajuba was immunoprecipitated (anti-MYC) and
precipitates were analyzed for co-precipitated SNAI1 (anti-FLAG). Samples were re-stained for Ajuba (anti-MYC) and lysates were control-stained for
expressed SNAI1 (anti-FLAG). B: Proposed mechanism of how PKD1-mediated phosphorylation regulates SNAI1 function as a transcriptional repressor
of E-cadherin gene expression.
doi:10.1371/journal.pone.0030459.g006
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gens. Secondary HRP-linked antibodies were from Roche (India-
napolis, IN). Secondary antibodies Alexa Fluor 568 F(ab9)2 fragment
of goat-anti-mouse IgG or Alexa Fluor 546 F(ab9)2 fragment of goat-
anti-rabbit were from Invitrogen (Carlsbad,CA). Mirus HeLa-
Monster (Mirus, Madison, WI) and Superfect (Qiagen, Valencia,
CA)wereusedfortransienttransfectionofHeLa,MirusTransIT-293
(Mirus) for Hek293, Lipofectamine 2000 (Invitrogen) for Panc1 and
MDCK, and GenJet (SignaGen Laboratories, Ijamsville, MD) for
NMuMG. Bradykinin and 12-phorbol 13-myristate acetate (PMA)
were from Sigma, EGF (epidermal growth factor) from PeproTech
(Rocky Hill, NJ) and CID755673 (2,3,4,5-Tetrahydro-7-hydroxy-
1H-benzofuro[2,3-c]azepin-1-one) from Tocris Bioscience (Ellisville,
MO). The PKD-specific substrate peptide used was AALVRQMS-
VAFFFK.
DNA Constructs
GFP-tagged human SNAI1 was obtained from Addgene
(Cambridge, MA) [18]. The expression construct for FLAG-
tagged SNAI1 was generated using above construct as a template
and 59-GCGGGATCCATGCCGCGCTCTTTCCTCGTCAG-
G-39 and 59-CGCCTCGAGTCATTTGTCATCATCGTCCT-
TATAGTCGCGGGGACATCCTGAGCAGCCGGA-39 as prim-
ers and by cloning into pcDNA4/TO (Invitrogen, Carlsbad, CA)
via BamHI and XhoI. The expression construct for a GST-SNAI1
fusion protein was generated by cloning the same fragment into
pGEX4-T1 via BamHI and XhoI. Mutagenesis was carried out
using the QuikChange kit (Stratagene, La Jolla, CA). The
SNAI1.S11A mutants were generated using 59-CTCGTCAG-
GAAGCCCGCCGACCCCAATCGGAAG-39 and 59-CTTC-
CGATTGGGGTCGGCGGGCTTCCTGACGAG-39, and the
Figure 7. Loss of nuclear PKD activity and SNAI1 phosphorylation at S11 are markers for invasive breast cancer. Tissue microarrays
(TMAs) including 10 normal breast tissue samples, 40 invasive ductal carcinoma of the breast and 10 metastatic invasive ductal carcinoma samples
from lymph nodes were H&E stained or analyzed for the expression of active PKD (anti-pY95-PKD), S11-phosphorylated SNAI1 (anti-pS11-SNAI1) and
total SNAI1 (anti-SNAI1). Representative pictures of normal (A–D) and 3 tumor tissues (E–P) are depicted. Numbers indicate the position of the tissue
on the TMA. The asterisk (sample #10) indicates tumor tissue form a region adjacent to the normal tissue (same patient). Inserts show enhanced area.
doi:10.1371/journal.pone.0030459.g007
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GACCCCAATCGGAAG-39 and 59-CTTCCGATTGGGGTC-
CTCGGGCTTCCTGACGAG-39 as primers. The expression
construct for MYC-tagged Ajuba was generated by amplification
of human Ajuba from a HeLa cDNA library using 59-GCGC-
TCGAGTCAGATATAGTTGGCAGGGGGTTG-39 and 59-GC-
GGGATCCATGGAACAAAAACTCATCTCAGAAGAGGAT-
CTGGAGCGGTTAGGAGAGAAAGCCAGT-39 as primers
and by cloning into pcDNA4/TO via BamHI and XhoI.
Expression plasmids for HA-tagged or GFP-tagged wildtype,
constitutively-active or kinase-inactive PKD1 were described
before [41]. The luciferase reporter construct pGL3-E-cadherin
promoter (2178/+92) from A. Garcia de Herreros, and the
expression construct for constitutively-active RhoA was described
previously [41]. The use of shRNA specifically-directed against
human PKD1/2 was described elsewhere [37,41]. The lentiviral
shRNA expression system to knock-down mouse PKD1 and
PKD2 expression is commercially available from Sigma (SHDNA
MISSIONH shRNA Plasmid DNA; St. Louis, MO, USA).
Sequences used were NM_008858.1-2104s1c1 and NM_
178900.2-827s1c1. The ViraPower Lentiviral Expression System
(Invitrogen) was used for an optimized mix of packaging plasmids
to produce Lentivirus in 293FT cells.
Cellular extracts, Immunoblotting, Immunoprecipitation
and PAGE
Cellular lysates. Cells were washed twice with ice-cold PBS
(140 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, 1.5 mM
KH2PO4, pH 7.2) and lysed with RIPA buffer (0.01 M
NaHPO4 pH 7.2, 2 mM EDTA, 50 mM NaF, 150 mM NaCl,
0.1% SDS, 1% sodium deoxycholate, 1% Nonindet P-40) for total
cell lysates, or Buffer A (50 mM Tris-HCl pH7.4, 1% Triton X-
100, 150 mM NaCl, 5 mM EDTA pH 7.4) plus Protease
Inhibitor Cocktail (PIC, Sigma-Aldrich, St. Louis, MO). Lysates
were vortexed and incubated on ice for 30 min. Following
centrifugation (13,000 rpm, 15 min, 4uC) the supernatant was
collected and subjected to SDS-PAGE (Western blotting) or
proteins of interest were immunoprecipitated by 1 hr incubation
with a specific antibody (2 mg) followed by 30 min incubation with
protein G-Sepharose (Amersham Biosciences). Immune-
complexes were washed 3 times with TBS (50 mM Tris-HCl
pH 7.4, 150 mM NaCl), resolved in 20 ml TBS and 26Laemmli
buffer and subjected to SDS-PAGE.
Nuclear extracts. Cells were washed twice with ice-cold
PBS, scraped in NE buffer I (10 mM HEPES pH 7.9, 10 mM
KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 1 mM
PMSF), incubated on ice (15 min) and supplemented with 10%
NP-40. Samples were lysed on a shaker (4uC, 2 min), centrifuged
(RT, 1 min, 13,000 rpm) and supernatant (cytosolic lysate) and
pellets (nuclei) were collected. Nuclei were lysed in NE buffer II
(20 mM HEPES pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM
EGTA, 1 mM DTT, 1 mM PMSF) by rough shaking for 20 min
at 4uC. Samples were then centrifuged (5 min, 4uC, 15,000 rpm)
to obtain nuclear lysates. Following separation by SDS-PAGE,
samples were transferred to nitrocellulose membranes and
visualized by immunostaining.
Reporter Gene Assays
Cells were transiently transfected with 2 mg pGL3-E-cadherin
promoter (-178/+92) luciferase reporter construct, 0.1 mg renilla
luciferase reporter and 1 mg of the cDNA of interest. 24 hr after
transfection cell lysates were prepared by washing cells twice with
ice-cold PBS, scraping in 250 ml Passive Lysis Buffer (Promega)
and centrifugation (13,000 rpm, 10 min, 4uC). Assays for
luciferase activity were performed on total cell lysates using a
Veritas luminometer (Symantec, Cupertino, CA). Protein expres-
sion was controlled by immunoblot analysis.
Chromatin Immunoprecipitation (ChIP) Assay
ChIP assays were performed using the EZ-ChIP
TM Chromatin
Immunoprecipitation (ChIP) KIT from Millipore (Bedford, MA)
according to the manufacturer’s protocol. 4 mg primary antibody
(anti-FLAG, anti-pS11-SNAI1) or IgG control were used for
immunoprecipitations. Immunoprecipitates were analyzed by
PCR using the following primer set: 59-AATCAGAACCGTG-
CAGGTCC-39 and 59-ACAGGTGCTTTGCAGTTCCG-39 to
amplify a 250 bp fragment of the human E-cadherin promoter
corresponding to an E2-box binding site or a previously-described
primer set to detect a 360 bp fragment of the mouse E-cadherin
promoter [41].
In Vitro Kinase Assays
Kinase assays with GST fusion proteins were carried out by
adding 250 ng of active, purified PKD1 (Upstate, Charlottesville,
VA) to 2 mg of purified GST-fusion protein in a volume of 40 ml
kinase buffer (50 mM Tris pH 7.4, 10 mM MgCl2 and 2 mM
DTT) supplemented with 100 mMA T P .T h ek i n a s er e a c t i o n
(30 min, RT) was stopped by adding 26Laemmli buffer. Kinase
assays to determine the activity of immunoprecipitated PKD1
were carried out as follows: PKD was immunoprecipitated and
20 ml kinase buffer (50 mM Tris/HCI pH 7.4, 10 mM MgCl2,
2 mM dithiothreitol) was added to the precipitates. The kinase
reaction was started by addition of 10 ml of kinase substrate
mixture (150 mM PKD-specific substrate peptide, 50 mMA T P ,
10 mCi of [c-
32P]ATP in kinase buffer) and carried out for
30 min at 37uC. The reaction was stopped and samples were
spotted onto P81 phosphocellulose filters (Whatman). Samples
were washed 3 times with 0.75% phosphoric acid, once with
acetone, air dried and radiolabel incorporation was determined
with scintillation counting. To determine stoichiometry, purified
SNAI1 (3 mg) was incubated with active PKD1 (100 ng) and
100 mM[ c-
32P]ATP in kinase buffer for 60 min at 37uC. The
reaction was stopped and aliquots were spotted onto P81
phosphocellulose filters. Samples were further processed as
above.
Immunofluorescence Microscopy
Cells were transfected or treated as indicated in 8 well ibiTreat
m-Slides (Ibidi, Martinsried, Germany). The next day cells were
washed twice with phosphate-buffered saline (PBS), fixed with 4%
paraformaldehyde (15 min, 37uC), washed three times in PBS,
permeabilized with 0.1% Triton X-100 in PBS for 2 min at room
temperature (RT) and then blocked with 3% bovine serum
albumin and 0.05% Tween 20 in PBS (blocking solution) for
30 min at RT. Samples were incubated for 2 hours at RT with
primary antibodies (anti-E-cadherin 1:500, anti-pS11-SNAI1
1:5000, or anti-FLAG 1:4000 for overexpressed SNAI1 and
SNAI1 mutants) diluted in blocking solution. Cells were washed
five times with PBS and incubated with secondary antibodies
(Alexa Fluor 568 F(ab9)2 fragment of goat-anti-mouse IgG or
Alexa Fluor 546 F(ab9)2 fragment of goat-anti-rabbit; both
Invitrogen), diluted (1:500) in blocking solution for 2 hours at
RT. Nuclei were stained with DAPI. After extensive washes in
PBS, cells were mounted in Ibidi mounting medium (Ibidi).
Samples were examined using an IX81 DSU Spinning Disc
Confocal from Olympus with a 406 objective. Images were
processed using NIH ImageJ.
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Tissue array slides containing histologically-confirmed human
breast cancer and normal human breast tissue samples (IMH-364/
CBA2) were purchased from Imgenex (San Diego, CA). The TMAs
were deparaffinized (one hour at 60uC), dewaxed in xylene (five
times for four minutes) and gradually rehydrated with ethanol
(100%, 95%, 75%, twice with each concentration for three
minutes). The rehydrated TMAs were rinsed in water and subjected
to antigen retrieval in citrate buffer (pH 6.0) as described by the
manufacturer (DAKO, Carpinteria, CA, USA). Slides were treated
with 3% hydrogen peroxide (five minutes) to reduce endogenous
peroxidase activity and washed with PBS containing 0.5% Tween
20. Active PKD1 and S11-phosphorylated SNAI1 were detected
using specific antibodies (anti-pY95-PKD at 1:200 and anti-pS11-
SNAI1 at 1:1000) in PBS/Tween and visualized using the Envision
Plus Dual Labeled Polymer Kit following the manufacturer’s
instructions (DAKO, Carpinteria, CA, USA). H&E staining was
performedaspreviously described[37].Images werecaptured using
ImagePro software (Media Cybernetics, Bethesda, MD, USA).
Statistical Analysis
Data are presented as mean 6 SD. P values were acquired with
the student’s t-test using Graph Pad software, and p,0.05 is
considered statistically significant.
Supporting Information
Figure S1 PKD1 regulates E-cadherin expression in
MDCK cells. MDCK cells were transfected with vector control,
constitutively-active PKD1 (PKD1.CA) or kinase-dead PKD1
(PKD1.KD). After 72 hours, samples were analyzed by Western
blot for E-cadherin expression (anti-E-cadherin), as well as ectopic
expression of PKD1 mutants (anti-PKD1). Staining for actin (anti-
actin) served as loading control. This data shows that PKD1
regulates E-cadherin expression in MDCK cancer cells. It also
shows that the kinase-dead PKD1 can act as dominant-negative
mutant.
(EPS)
Figure S2 Control blots for Fig. 3E and 3F. Lysates of the
samples were control-stained for GST-RhoA.CA or GST
expression using anti-GST antibody.
(EPS)
Figure S3 Blunting or mimicking mutations for pS11 do
not impact SNAI1 localization. Panc1 cells were transfected
with GFP control, GFP-SNAI1, GFP-SNAI1.S11A or GFP-
SNAI1.S11E mutants. Localization of GFP or GFP-tagged
proteins was determined after 16 hrs using immunofluorescence
analysis (bar is 25 mm).
(EPS)
Figure S4 The anti-pS11-SNAI1 antibody specifically
immunoprecipitates PKD1-phosphorylated SNAI1.
Hek293T cells were transfected with vector control, FLAG-SNAI1
or active PKD1 (PKD1.CA, PKD1.S738E.S742E) as indicated.
Phospho-S11-SNAI1 was immunoprecipitated (anti-pS11-SNAI1)
and samples were subjected to SDS-PAGE and analyzed in
immunoblots using an anti-FLAG antibody to detect immuno-
precipitated SNAI1. Control Western blots were performed to
detect PKD1.CA input (anti-PKD1) or for vimentin (anti-
vimentin) as loading control.
(EPS)
Figure S5 Specificity of nuclear pS11-SNAI1 staining in
normal ductal breast tissue. Normal breast tissue was
immunohistochemically-stained with anti-pS11-SNAI1 (left side).
To confirm specificity, the anti-pS11-SNAI1 antibody was
incubated for one hour with a 100-fold molar excess of the
pS11-peptide used as antigen prior to use in immunohistochem-
istry (right side). This data shows that obtained results showing
pS11-SNAI1 in nuclei of normal breast ductal tissue represent
specific staining.
(EPS)
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